+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression



MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression



International Journal of Cancer 87(1): 55-60, 1 July



A number of genes of the MAGE-A, B, and C families have been shown to code for antigens that are recognized on many human tumors by autologous cytolytic T lymphocytes. These antigens ought to be strictly tumor specific because the encoding MAGE genes are not expressed in normal adult cells except for male germline cells, which lack HLA expression. To identify new genes of this type, we performed representational difference analysis on a melanoma cell line by subtraction with a normal skin sample. This led to the identification of MAGE-C2, a new member of the MAGE-C family. A search for nucleotide sequences encoding MAGE-like proteins in public databases led to the identification of three additional MAGE genes, which were named MAGE-B5, MAGE-B6, and MAGE-C3. The four new MAGE genes are not expressed in normal tissues, except for testis, and are expressed in tumors of different histological origins. Therefore, like other MAGE genes expressed specifically in tumors, MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3 ought to encode antigens that could be targets for cancer immunotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 010945461

Download citation: RISBibTeXText

PMID: 10861452

DOI: 10.1002/1097-0215(20000701)87:1<55::aid-ijc8>3.0.co;2-j


Related references

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. British Journal of Ophthalmology 96(3): 451-458, 2012

Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas; lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2. Anticancer Research 18(5b): 3639-3644, 1998

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Molecular Cancer Research 5(7): 749-759, 2007

Expression of MAGE-1, MAGE-2, MAGE-3/-6, and MAGE-4a/-4b genes in ovarian tumors. International Journal Of Cancer. 64(6): 388-393, 1995

High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32(45): 5901-5907, 2015

MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo. Cancer Immunology, ImmunoTherapy 55(7): 841-849, 2005

High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head and Neck 33(5): 702-707, 2011

Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immunity 3: 9, 2003

Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene products. Official Gazette of the United States Patent & Trademark Office Patents 121(2): 1630-1631, June 9, 1998

MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Research 67(20): 9954-9962, 2007

Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof. Official Gazette of the United States Patent & Trademark Office Patents 1278(3), Jan 20, 2004

Expression of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and malignant thyroid diseases. Head and Neck 33(10): 1426-1432, 2012

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 66(1): 13-18, 2005

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in squamous cell carcinoma of the penis. Urology 68(1): 205-207, 2006

MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof. Official Gazette of the United States Patent & Trademark Office Patents 1242(3), Jan 16, 2001